AIM Schedule One - Motif Bio plc (7910Z)
26 Mayo 2021 - 10:00AM
UK Regulatory
TIDMMTFB
RNS Number : 7910Z
AIM
26 May 2021
ANNOUNCEMENT TO BE MADE BY THE AIM APPLICANT PRIOR TO ADMISSION
IN ACCORDANCE WITH RULE 2 OF THE AIM RULES FOR COMPANIES ("AIM
RULES")
COMPANY NAME:
Motif Bio plc ("Motif" or the "Company").
The Company is proposing to change its name to BiVictriX Therapeutics
plc upon completion of a reverse takeover ("RTO") of BiVictriX
Therapeutics Limited ("BVX"), together the Enlarged Group.
COMPANY REGISTERED OFFICE ADDRESS AND IF DIFFERENT, COMPANY
TRADING ADDRESS (INCLUDING POSTCODES):
Motif:
201 Temple Chambers
3-7 Temple Avenue
London
EC4Y 0DT
BVX:
Optic Technium
St. Asaph Business Park
Fford William Morgan
St. Asaph, Wales
LL17 0JD
Post Admission:
Alderley Park,
Congleton Road
Nether Alderley
Macclesfield
SK10 4TG
COUNTRY OF INCORPORATION:
England and Wales
COMPANY WEBSITE ADDRESS CONTAINING ALL INFORMATION REQUIRED
BY AIM RULE 26:
www.bivictrix.com (on Admission).
COMPANY BUSINESS (INCLUDING MAIN COUNTRY OF OPERATION) OR,
IN THE CASE OF AN INVESTING COMPANY, DETAILS OF ITS INVESTING
POLICY). IF THE ADMISSION IS SOUGHT AS A RESULT OF A REVERSE
TAKE-OVER UNDER RULE 14, THIS SHOULD BE STATED:
Motif is currently classified as an AIM Rule 15 cash shell.
It proposes to acquire 100 per cent. of BVX by way of an RTO
under AIM Rule 14.
BVX is a UK based drug development company which was incorporated
in February 2016 and has developed its proprietary Bi-Cygni(R)
technology. This technology utilises Antibody Drug Conjugates
("ADC"s), an existing class of potent biological drugs, for
the treatment of various cancers including Acute Myeloid Leukaemia,
the first condition which BVX intends to treat.
BVX has identified a unique, cancer-restricted antigen fingerprint,
absent from healthy cells, which can be exploited to produce
cancer selective therapeutics. The Bi-Cygni(R) technology has
been developed to exploit this concept and expedite the development
of bispecific therapeutics with an improved therapeutic index.
Based on BVX's work to date, these ADCs demonstrate superior
potency and tumour selectivity compared to conventional ADCs.
The main country of operation is in the UK.
DETAILS OF SECURITIES TO BE ADMITTED INCLUDING ANY RESTRICTIONS
AS TO TRANSFER OF THE SECURITIES (i.e. where known, number
and type of shares, nominal value and issue price to which
it seeks admission and the number and type to be held as treasury
shares):
80,979,876 ordinary shares of GBP0.022 par value each in the
capital of the Company, following a proposed share consolidation
("Ordinary Shares").
No restrictions on transferability.
CAPITAL TO BE RAISED ON ADMISSION (AND/OR SECONDARY OFFERING)
AND ANTICIPATED MARKET CAPITALISATION ON ADMISSION:
Capital to be raised on Admission: Gross proceeds of GBP10.1
million
Anticipated market capitalisation on Admission: GBP16.2 million
PERCENTAGE OF AIM SECURITIES NOT IN PUBLIC HANDS AT ADMISSION:
17 per cent
DETAILS OF ANY OTHER EXCHANGE OR TRADING PLATFORM TO WHICH
THE AIM SECURITIES (OR OTHER SECURITIES OF THE COMPANY) ARE
OR WILL BE ADMITTED OR TRADED:
N/A
FULL NAMES AND FUNCTIONS OF DIRECTORS AND PROPOSED DIRECTORS
(underlining the first name by which each is known or including
any other name by which each is known):
Existing Directors:
Bruce Andrew Williams (Chairman)*
Jonathan Eliot Gold (Non-Executive Director)
Graham George Lumsden (Non-Executive Director)*
Christopher Thomas Wardhaugh (Non-Executive Director)*
Proposed Directors:
Tiffany Jane Thorn (Chief Executive Officer)
Iain Gladstone Ross (Non-Executive Chairman)
Dr. Ole Petter Veiby (Non-Executive Director)
Professor Robert Edward Hawkins (Non-Executive Director)
*On Admission, Bruce Williams, Graham Lumsden and Christopher
Wardhaugh will step down from the Board.
FULL NAMES AND HOLDINGS OF SIGNIFICANT SHAREHOLDERS EXPRESSED
AS A PERCENTAGE OF THE ISSUED SHARE CAPITAL, BEFORE AND AFTER
ADMISSION (underlining the first name by which each is known
or including any other name by which each is known):
Percentage Number of Percentage
Number of of Existing Ordinary of
Ordinary Ordinary Shares Enlarged
Name Shares* Shares immediately Issued
following Share Capital
Admission
Development Bank of
Wales 9,405,654 28% 11,510,562 14.2%
Canaccord Genuity - - 6,000,000 7.4%
Ora Capital - - 5,000,000 6.2%
Robert Keith - - 5,000,000 6.2%
Alderley Park
Ventures 4,578,079 14% 4,466,495 5.5%
Patronus Partners - - 3,600,000 4.5%
Optiva Securities - - 3,587,871 4.4%
Cleveland Capital - - 2,700,000 3.3%
Bio City Investments 2,252,809 7% 2,242,081 2.7%
Future Fund 2,252,809 7% 2,242,081 2.7%
Tiffany Thorn 1,745,989 5% 1,540,258 1.9%
* Based on current BVX holding on a pre-consolidation basis
NAMES OF ALL PERSONS TO BE DISCLOSED IN ACCORDANCE WITH SCHEDULE
2, PARAGRAPH (H) OF THE AIM RULES:
N/A
(i) ANTICIPATED ACCOUNTING REFERENCE DATE
(ii) DATE TO WHICH THE MAIN FINANCIAL INFORMATION IN THE ADMISSION
DOCUMENT HAS BEEN PREPARED (this may be represented by unaudited
interim financial information)
(iii) DATES BY WHICH IT MUST PUBLISH ITS FIRST THREE REPORTS
PURSUANT TO AIM RULES 18 AND 19:
(i) 31 December
(ii) Audited results to 31 December 2020 for both Motif and
BVX
(iii) Accounts for 6 month period ended 30 June 2021 (to be
notified by 30 September 2021); Accounts for 12 month period
ended 31 December 2021 (by 30 June 2022); Accounts for 6 months
ended 30 June 2022 (by 30 September 2022).
EXPECTED ADMISSION DATE:
15 June 2021
NAME AND ADDRESS OF NOMINATED ADVISER:
S.P. Angel Corporate Finance LLP, Prince Frederick House, 35-39
Maddox Street, Mayfair, London, W1S 2PP
NAME AND ADDRESS OF BROKER:
S.P. Angel Corporate Finance LLP, Prince Frederick House, 35-39
Maddox Street, Mayfair, London, W1S 2PP
OTHER THAN IN THE CASE OF A QUOTED APPLICANT, DETAILS OF WHERE
(POSTAL OR INTERNET ADDRESS) THE ADMISSION DOCUMENT WILL BE
AVAILABLE FROM, WITH A STATEMENT THAT THIS WILL CONTAIN FULL
DETAILS ABOUT THE APPLICANT AND THE ADMISSION OF ITS SECURITIES:
Copies of this document will be available free of charge to
the public during normal business hours on any day (Saturdays,
Sundays and public holidays excepted) at the offices of S.P.
Angel Corporate Finance LLP, Prince Frederick House, 35-39
Maddox Street, Mayfair, London, W1S 2PP in accordance with
the AIM Rules. This document will also be available for download
from the Company's website at www.motifbio.com up to Admission
and at www.bivictrix.com post Admission.
THE CORPORATE GOVERNANCE CODE THE APPLICANT HAS DECIDED TO
APPLY
The Enlarged Group will adopt the QCA Corporate Governance
Code, as published by the Quoted Companies Alliance.
DATE OF NOTIFICATION:
26 May 2021
NEW/ UPDATE:
New
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
PAAUVUNRAAUVUAR
(END) Dow Jones Newswires
May 26, 2021 11:00 ET (15:00 GMT)
Motif Bio (LSE:MTFB)
Gráfica de Acción Histórica
De Nov 2024 a Dic 2024
Motif Bio (LSE:MTFB)
Gráfica de Acción Histórica
De Dic 2023 a Dic 2024
